(Q40419399)

20 September 2017

title

Zanamivir: an influenza virus neuraminidase inhibitor (English)

1 reference

20 September 2017

1 reference

Colman PM

1

1 reference

20 September 2017

publication date

1 April 2005

1 reference

Expert Review of Anti-infective Therapy

20 September 2017

published in

1 reference

20 September 2017

volume

3

1 reference

20 September 2017

issue

2

1 reference

20 September 2017

page(s)

191-199

1 reference

Origin and evolution of the 1918 "Spanish" influenza virus hemagglutinin gene

20 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

The structure and receptor binding properties of the 1918 influenza hemagglutinin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Enhanced virulence of influenza A viruses with the haemagglutinin of the 1918 pandemic virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Lack of infrastructure hampers virus monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Avian H5N1 influenza in cats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Influenza virus neuraminidase: structure, antibodies, and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Structure of the catalytic and antigenic sites in influenza virus neuraminidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Refined atomic structures of N9 subtype influenza virus neuraminidase and escape mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Rational design of potent sialidase-based inhibitors of influenza virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Three-dimensional structure of the complex of 4-guanidino-Neu5Ac2en and influenza virus neuraminidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis, and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 1. Discovery, synthesis, biological activity, and structure-activity relationships of 4-guanidino- and 4-amino-4H-pyran-6-carboxamides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Dihydropyrancarboxamides related to zanamivir: a new series of inhibitors of influenza virus sialidases. 2. Crystallographic and molecular modeling study of complexes of 4-amino-4H-pyran-6-carboxamides and sialidase from influenza virus types A and B

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

A novel means of identifying the neuraminidase type of currently circulating human A(H1) influenza viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Existing antivirals are effective against influenza viruses with genes from the 1918 pandemic virus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Role of neuraminidase in lethal synergism between influenza virus and Streptococcus pneumoniae

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Structure of the haemagglutinin-neuraminidase from human parainfluenza virus type III

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Zanamivir: an update of its use in influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Zanamivir: a review of its use in influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is a potent inhibitor of influenza virus in ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

A population pharmacokinetic analysis of zanamivir in subjects with experimental and naturally occurring influenza: effects of formulation and route of administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Direct measurement of the anti-influenza agent zanamivir in the respiratory tract following inhalation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Clinical efficacy and safety of the orally inhaled neuraminidase inhibitor zanamivir in the treatment of influenza: a randomized, double-blind, placebo-controlled European study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Zanamivir in the treatment of influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. GG167 Influenza Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Efficacy and safety of the neuraminidase inhibitor zanamivirin the treatment of influenza A and B virus infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Zanamivir for treatment of symptomatic influenza A and B infection in children five to twelve years of age: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Antiviral treatment and prophylaxis of influenza in primary care: German recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Efficacy of zanamivir for chemoprophylaxis of nursing home influenza outbreaks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Inhaled zanamivir for the prevention of influenza in families. Zanamivir Family Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Emergence and apparent transmission of rimantadine-resistant influenza A virus in families

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Prevention of influenza in the general population

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Prevention of influenza in the general population: recommendation statement from the Canadian Task Force on Preventive Health Care

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Tackling the next influenza pandemic

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Containing pandemic influenza with antiviral agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Zanamivir: a review of clinical safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Zanamivir: a review of clinical safety in individuals at high risk of developing influenza-related complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Generation and characterization of an influenza virus neuraminidase variant with decreased sensitivity to the neuraminidase-specific inhibitor 4-guanidino-Neu5Ac2en

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Molecular basis for the resistance of influenza viruses to 4-guanidino-Neu5Ac2en

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Mutations affecting the sensitivity of the influenza virus neuraminidase to 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Drug design against a shifting target: a structural basis for resistance to inhibitors in a variant of influenza virus neuraminidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Resistant influenza A viruses in children treated with oseltamivir: descriptive study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Mutation in the influenza virus neuraminidase gene resulting in decreased sensitivity to the neuraminidase inhibitor 4-guanidino-Neu5Ac2en leads to instability of the enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Resistance of influenza viruses to neuraminidase inhibitors--a review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Zanamivir susceptibility monitoring and characterization of influenza virus clinical isolates obtained during phase II clinical efficacy studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Perspectives on antiviral use during pandemic influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Oral oseltamivir treatment of influenza in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Influenza virus carrying neuraminidase with reduced sensitivity to oseltamivir carboxylate has altered properties in vitro and is compromised for infectivity and replicative ability in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Oseltamivir-resistant influenza?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Position statement: global neuraminidase inhibitor susceptibility network

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Susceptibility of human influenza viruses from Australasia and South East Asia to the neuraminidase inhibitors zanamivir and oseltamivir

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Influenza: old and new threats

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Molecular cloning and characterization of NEU4, the fourth member of the human sialidase gene family

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Molecular cloning and characterization of a plasma membrane-associated sialidase specific for gangliosides

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Up-regulation of plasma membrane-associated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Neuraminidase inhibitor, oseltamivir blocks GM1 ganglioside-regulated excitatory opioid receptor-mediated hyperalgesia, enhances opioid analgesia and attenuates tolerance in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Severe acute respiratory syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Influenza: girding for disaster. Looking the pandemic in the eye

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Influenza: girding for disaster. Facing down pandemic flu, the world's defenses are weak

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Pharmacokinetics of zanamivir after intravenous, oral, inhaled or intranasal administration to healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Pharmacoscintigraphic evaluation of lung deposition of inhaled zanamivir in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

Mucin as substrate of enzyme action by viruses of the mumps influenza group

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14787210.3.2.191

21 January 2018

Identifiers

DOI

10.1586/14787210.3.2.191

1 reference

20 September 2017

1 reference